Bio News
North Immunology plans to list on Nasdaq next year through a reverse merger with Aeslon Medical.
Following the merger, North Immunology investors will own 95.25% of the newly formed entity, while Aeslon shareholders will receive the remaining stake along with contingent value rights (CVRs) tied to revenue from the existing Hemopurifier business.
The newly formed entity will trade under the ticker NRTX and plans to fund operations through the second half of 2028 with $180 million (approximately 241.2 billion won) in private investment.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
